Investing in Cabaletta Bio for potential high returns on innovative CAR-T therapies despite volatility and risk. Click here ...

At the Neurocritical Care Society's (NCS) 22nd Annual Meeting this week, a University of Cincinnati researcher presented ...

Albert Roy, president and CEO of the Lupus Research Alliance, speaks with CBS News New York's Tony Sadiku at the Walk to End ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Kezar Life Sciences announced the termination of Phase 2b PALIZADE clinical trial of zetomipzomib, an investigational therapy ...

Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...

On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active ...

Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on developing the drug for a rare chronic ...

Thousands of passionate people with lupus and those who care about the cause will join together Saturday, October 19 at the ...

The primary objective is to evaluate the safety of CLN-978 for the treatment of active moderate to severe SLE, with secondary ...